Global Arthritis Drug

Arthritis Drug Comprehensive Study by Type (Synthetic DMARDs, Biological DMARDs, NSAIDs, Corticosteroids, Analgesics), Application (Retail Pharmacies, Hospital Pharmacies, Drug Stores, E-Commerce), Route of Administration (Oral, Parenteral, Topical), Arthritis (Degenerative Arthritis (Osteoarthritis), Inflammatory Arthritis (Rheumatoid Arthritis), Infectious Arthritis, Metabolic Arthritis) Players and Region - Global Market Outlook to 2026

Arthritis Drug Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Arthritis Drug Market Overview:
Arthritis drugs are used to treat joint inflammation. Arthritis may affect a single joint or many. Arthritis affects people of all ages, genders, and races, and it is the leading cause of disability in the United States. The most common signs of arthritis are joint pain, stiffness, and swelling. According to reports, over 50 million adults and 300,000 children suffer from arthritis. It is more common in women than in men, and it affects people over the age of 65. Rheumatoid arthritis has a global annual incidence of 3 cases per 10,000 people and a prevalence rate of 1%, rising with age and peaking between the ages of 35 and 50. Throughout the forecast period, rising cases of rheumatoid arthritis and osteoarthritis will drive market development.

Growth Drivers
  • Increasing prevalence in geriatric population especially women
  • Growing Use of Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Market Trends
  • Self-Awareness And Pro-Activeness To Seek Treatment

Roadblocks
  • High Cost Of Arthritis Drugs

Opportunities
  • Increasing Obese Population Around The Globe
  • Rising Awareness About The Therapeutics In Emerging Economies

Challenges
  • Growing Demand For Low-Priced Generics


Competitive Landscape:
The global arthritis drugs market is highly competitive and consists of a limited number of vendors who compete with each other. The intense competition, changing consumer spending patterns, and demographic trends pose significant risk factors for manufacturer’s growth.
Some of the key players profiled in the report are Novartis AG (Switzerland), Eli Lilly and Company (United States), Amgen Inc. (United States), Merck & Co., Inc. (United States), Bristol-Myers Squibb Company (United States), Pfizer Inc. (United States), Johnson & Johnson (United States), F. Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany) and Sanofi S.A. (France). Analyst at AMA Research see United States Players to retain maximum share of Global Arthritis Drug market by 2026. Considering Market by Route of Administration, the sub-segment i.e. Oral will boost the Arthritis Drug market. Considering Market by Arthritis , the sub-segment i.e. Degenerative Arthritis (Osteoarthritis) will boost the Arthritis Drug market.

On 26th January 2021, Rinvoq received European Commission (EC) approval for its drug named Rinvoq. This drug is for oral consumption once-daily and is used to treat psoriatic arthritis (PsA). Rinvoq previously received FDA and EMA approval for rheumatoid arthritis (RA) in 2019

What Can be Explored with the Arthritis Drug Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Arthritis Drug Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Arthritis Drug
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Arthritis Drug market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Arthritis Drug market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Arthritis Drugs Providers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists, Private Equity Firms, Government Regulatory and Research Organizations and End-User Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Synthetic DMARDs
  • Biological DMARDs
  • NSAIDs
  • Corticosteroids
  • Analgesics
By Application
  • Retail Pharmacies
  • Hospital Pharmacies
  • Drug Stores
  • E-Commerce
By Route of Administration
  • Oral
  • Parenteral
  • Topical

By Arthritis
  • Degenerative Arthritis (Osteoarthritis)
  • Inflammatory Arthritis (Rheumatoid Arthritis)
  • Infectious Arthritis
  • Metabolic Arthritis

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing prevalence in geriatric population especially women
      • 3.2.2. Growing Use of Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • 3.3. Market Challenges
      • 3.3.1. Growing Demand For Low-Priced Generics
    • 3.4. Market Trends
      • 3.4.1. Self-Awareness And Pro-Activeness To Seek Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Arthritis Drug, by Type, Application, Route of Administration, Arthritis and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Arthritis Drug (Value)
      • 5.2.1. Global Arthritis Drug by: Type (Value)
        • 5.2.1.1. Synthetic DMARDs
        • 5.2.1.2. Biological DMARDs
        • 5.2.1.3. NSAIDs
        • 5.2.1.4. Corticosteroids
        • 5.2.1.5. Analgesics
      • 5.2.2. Global Arthritis Drug by: Application (Value)
        • 5.2.2.1. Retail Pharmacies
        • 5.2.2.2. Hospital Pharmacies
        • 5.2.2.3. Drug Stores
        • 5.2.2.4. E-Commerce
      • 5.2.3. Global Arthritis Drug by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Parenteral
        • 5.2.3.3. Topical
      • 5.2.4. Global Arthritis Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Arthritis Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Eli Lilly and Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Amgen Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co., Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bristol-Myers Squibb Company (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Johnson & Johnson (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bayer AG (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sanofi S.A. (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Arthritis Drug Sale, by Type, Application, Route of Administration, Arthritis and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Arthritis Drug (Value)
      • 7.2.1. Global Arthritis Drug by: Type (Value)
        • 7.2.1.1. Synthetic DMARDs
        • 7.2.1.2. Biological DMARDs
        • 7.2.1.3. NSAIDs
        • 7.2.1.4. Corticosteroids
        • 7.2.1.5. Analgesics
      • 7.2.2. Global Arthritis Drug by: Application (Value)
        • 7.2.2.1. Retail Pharmacies
        • 7.2.2.2. Hospital Pharmacies
        • 7.2.2.3. Drug Stores
        • 7.2.2.4. E-Commerce
      • 7.2.3. Global Arthritis Drug by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Parenteral
        • 7.2.3.3. Topical
      • 7.2.4. Global Arthritis Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Arthritis Drug: by Type(USD Million)
  • Table 2. Arthritis Drug Synthetic DMARDs , by Region USD Million (2015-2020)
  • Table 3. Arthritis Drug Biological DMARDs , by Region USD Million (2015-2020)
  • Table 4. Arthritis Drug NSAIDs , by Region USD Million (2015-2020)
  • Table 5. Arthritis Drug Corticosteroids , by Region USD Million (2015-2020)
  • Table 6. Arthritis Drug Analgesics , by Region USD Million (2015-2020)
  • Table 7. Arthritis Drug: by Application(USD Million)
  • Table 8. Arthritis Drug Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 9. Arthritis Drug Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 10. Arthritis Drug Drug Stores , by Region USD Million (2015-2020)
  • Table 11. Arthritis Drug E-Commerce , by Region USD Million (2015-2020)
  • Table 12. Arthritis Drug: by Route of Administration(USD Million)
  • Table 13. Arthritis Drug Oral , by Region USD Million (2015-2020)
  • Table 14. Arthritis Drug Parenteral , by Region USD Million (2015-2020)
  • Table 15. Arthritis Drug Topical , by Region USD Million (2015-2020)
  • Table 16. South America Arthritis Drug, by Country USD Million (2015-2020)
  • Table 17. South America Arthritis Drug, by Type USD Million (2015-2020)
  • Table 18. South America Arthritis Drug, by Application USD Million (2015-2020)
  • Table 19. South America Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 20. South America Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 21. Brazil Arthritis Drug, by Type USD Million (2015-2020)
  • Table 22. Brazil Arthritis Drug, by Application USD Million (2015-2020)
  • Table 23. Brazil Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 24. Brazil Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 25. Argentina Arthritis Drug, by Type USD Million (2015-2020)
  • Table 26. Argentina Arthritis Drug, by Application USD Million (2015-2020)
  • Table 27. Argentina Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 28. Argentina Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 29. Rest of South America Arthritis Drug, by Type USD Million (2015-2020)
  • Table 30. Rest of South America Arthritis Drug, by Application USD Million (2015-2020)
  • Table 31. Rest of South America Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 32. Rest of South America Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 33. Asia Pacific Arthritis Drug, by Country USD Million (2015-2020)
  • Table 34. Asia Pacific Arthritis Drug, by Type USD Million (2015-2020)
  • Table 35. Asia Pacific Arthritis Drug, by Application USD Million (2015-2020)
  • Table 36. Asia Pacific Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 37. Asia Pacific Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 38. China Arthritis Drug, by Type USD Million (2015-2020)
  • Table 39. China Arthritis Drug, by Application USD Million (2015-2020)
  • Table 40. China Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 41. China Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 42. Japan Arthritis Drug, by Type USD Million (2015-2020)
  • Table 43. Japan Arthritis Drug, by Application USD Million (2015-2020)
  • Table 44. Japan Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 45. Japan Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 46. India Arthritis Drug, by Type USD Million (2015-2020)
  • Table 47. India Arthritis Drug, by Application USD Million (2015-2020)
  • Table 48. India Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 49. India Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 50. South Korea Arthritis Drug, by Type USD Million (2015-2020)
  • Table 51. South Korea Arthritis Drug, by Application USD Million (2015-2020)
  • Table 52. South Korea Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 53. South Korea Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 54. Taiwan Arthritis Drug, by Type USD Million (2015-2020)
  • Table 55. Taiwan Arthritis Drug, by Application USD Million (2015-2020)
  • Table 56. Taiwan Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 57. Taiwan Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 58. Australia Arthritis Drug, by Type USD Million (2015-2020)
  • Table 59. Australia Arthritis Drug, by Application USD Million (2015-2020)
  • Table 60. Australia Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 61. Australia Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Arthritis Drug, by Type USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Arthritis Drug, by Application USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 66. Europe Arthritis Drug, by Country USD Million (2015-2020)
  • Table 67. Europe Arthritis Drug, by Type USD Million (2015-2020)
  • Table 68. Europe Arthritis Drug, by Application USD Million (2015-2020)
  • Table 69. Europe Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 70. Europe Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 71. Germany Arthritis Drug, by Type USD Million (2015-2020)
  • Table 72. Germany Arthritis Drug, by Application USD Million (2015-2020)
  • Table 73. Germany Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 74. Germany Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 75. France Arthritis Drug, by Type USD Million (2015-2020)
  • Table 76. France Arthritis Drug, by Application USD Million (2015-2020)
  • Table 77. France Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 78. France Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 79. Italy Arthritis Drug, by Type USD Million (2015-2020)
  • Table 80. Italy Arthritis Drug, by Application USD Million (2015-2020)
  • Table 81. Italy Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 82. Italy Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 83. United Kingdom Arthritis Drug, by Type USD Million (2015-2020)
  • Table 84. United Kingdom Arthritis Drug, by Application USD Million (2015-2020)
  • Table 85. United Kingdom Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 86. United Kingdom Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 87. Netherlands Arthritis Drug, by Type USD Million (2015-2020)
  • Table 88. Netherlands Arthritis Drug, by Application USD Million (2015-2020)
  • Table 89. Netherlands Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 90. Netherlands Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 91. Rest of Europe Arthritis Drug, by Type USD Million (2015-2020)
  • Table 92. Rest of Europe Arthritis Drug, by Application USD Million (2015-2020)
  • Table 93. Rest of Europe Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 94. Rest of Europe Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 95. MEA Arthritis Drug, by Country USD Million (2015-2020)
  • Table 96. MEA Arthritis Drug, by Type USD Million (2015-2020)
  • Table 97. MEA Arthritis Drug, by Application USD Million (2015-2020)
  • Table 98. MEA Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 99. MEA Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 100. Middle East Arthritis Drug, by Type USD Million (2015-2020)
  • Table 101. Middle East Arthritis Drug, by Application USD Million (2015-2020)
  • Table 102. Middle East Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 103. Middle East Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 104. Africa Arthritis Drug, by Type USD Million (2015-2020)
  • Table 105. Africa Arthritis Drug, by Application USD Million (2015-2020)
  • Table 106. Africa Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 107. Africa Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 108. North America Arthritis Drug, by Country USD Million (2015-2020)
  • Table 109. North America Arthritis Drug, by Type USD Million (2015-2020)
  • Table 110. North America Arthritis Drug, by Application USD Million (2015-2020)
  • Table 111. North America Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 112. North America Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 113. United States Arthritis Drug, by Type USD Million (2015-2020)
  • Table 114. United States Arthritis Drug, by Application USD Million (2015-2020)
  • Table 115. United States Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 116. United States Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 117. Canada Arthritis Drug, by Type USD Million (2015-2020)
  • Table 118. Canada Arthritis Drug, by Application USD Million (2015-2020)
  • Table 119. Canada Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 120. Canada Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 121. Mexico Arthritis Drug, by Type USD Million (2015-2020)
  • Table 122. Mexico Arthritis Drug, by Application USD Million (2015-2020)
  • Table 123. Mexico Arthritis Drug, by Route of Administration USD Million (2015-2020)
  • Table 124. Mexico Arthritis Drug, by Arthritis USD Million (2015-2020)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Arthritis Drug: by Type(USD Million)
  • Table 136. Arthritis Drug Synthetic DMARDs , by Region USD Million (2021-2026)
  • Table 137. Arthritis Drug Biological DMARDs , by Region USD Million (2021-2026)
  • Table 138. Arthritis Drug NSAIDs , by Region USD Million (2021-2026)
  • Table 139. Arthritis Drug Corticosteroids , by Region USD Million (2021-2026)
  • Table 140. Arthritis Drug Analgesics , by Region USD Million (2021-2026)
  • Table 141. Arthritis Drug: by Application(USD Million)
  • Table 142. Arthritis Drug Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 143. Arthritis Drug Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 144. Arthritis Drug Drug Stores , by Region USD Million (2021-2026)
  • Table 145. Arthritis Drug E-Commerce , by Region USD Million (2021-2026)
  • Table 146. Arthritis Drug: by Route of Administration(USD Million)
  • Table 147. Arthritis Drug Oral , by Region USD Million (2021-2026)
  • Table 148. Arthritis Drug Parenteral , by Region USD Million (2021-2026)
  • Table 149. Arthritis Drug Topical , by Region USD Million (2021-2026)
  • Table 150. South America Arthritis Drug, by Country USD Million (2021-2026)
  • Table 151. South America Arthritis Drug, by Type USD Million (2021-2026)
  • Table 152. South America Arthritis Drug, by Application USD Million (2021-2026)
  • Table 153. South America Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 154. South America Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 155. Brazil Arthritis Drug, by Type USD Million (2021-2026)
  • Table 156. Brazil Arthritis Drug, by Application USD Million (2021-2026)
  • Table 157. Brazil Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 158. Brazil Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 159. Argentina Arthritis Drug, by Type USD Million (2021-2026)
  • Table 160. Argentina Arthritis Drug, by Application USD Million (2021-2026)
  • Table 161. Argentina Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 162. Argentina Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 163. Rest of South America Arthritis Drug, by Type USD Million (2021-2026)
  • Table 164. Rest of South America Arthritis Drug, by Application USD Million (2021-2026)
  • Table 165. Rest of South America Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 166. Rest of South America Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 167. Asia Pacific Arthritis Drug, by Country USD Million (2021-2026)
  • Table 168. Asia Pacific Arthritis Drug, by Type USD Million (2021-2026)
  • Table 169. Asia Pacific Arthritis Drug, by Application USD Million (2021-2026)
  • Table 170. Asia Pacific Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 171. Asia Pacific Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 172. China Arthritis Drug, by Type USD Million (2021-2026)
  • Table 173. China Arthritis Drug, by Application USD Million (2021-2026)
  • Table 174. China Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 175. China Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 176. Japan Arthritis Drug, by Type USD Million (2021-2026)
  • Table 177. Japan Arthritis Drug, by Application USD Million (2021-2026)
  • Table 178. Japan Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 179. Japan Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 180. India Arthritis Drug, by Type USD Million (2021-2026)
  • Table 181. India Arthritis Drug, by Application USD Million (2021-2026)
  • Table 182. India Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 183. India Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 184. South Korea Arthritis Drug, by Type USD Million (2021-2026)
  • Table 185. South Korea Arthritis Drug, by Application USD Million (2021-2026)
  • Table 186. South Korea Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 187. South Korea Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 188. Taiwan Arthritis Drug, by Type USD Million (2021-2026)
  • Table 189. Taiwan Arthritis Drug, by Application USD Million (2021-2026)
  • Table 190. Taiwan Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 191. Taiwan Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 192. Australia Arthritis Drug, by Type USD Million (2021-2026)
  • Table 193. Australia Arthritis Drug, by Application USD Million (2021-2026)
  • Table 194. Australia Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 195. Australia Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 196. Rest of Asia-Pacific Arthritis Drug, by Type USD Million (2021-2026)
  • Table 197. Rest of Asia-Pacific Arthritis Drug, by Application USD Million (2021-2026)
  • Table 198. Rest of Asia-Pacific Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 199. Rest of Asia-Pacific Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 200. Europe Arthritis Drug, by Country USD Million (2021-2026)
  • Table 201. Europe Arthritis Drug, by Type USD Million (2021-2026)
  • Table 202. Europe Arthritis Drug, by Application USD Million (2021-2026)
  • Table 203. Europe Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 204. Europe Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 205. Germany Arthritis Drug, by Type USD Million (2021-2026)
  • Table 206. Germany Arthritis Drug, by Application USD Million (2021-2026)
  • Table 207. Germany Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 208. Germany Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 209. France Arthritis Drug, by Type USD Million (2021-2026)
  • Table 210. France Arthritis Drug, by Application USD Million (2021-2026)
  • Table 211. France Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 212. France Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 213. Italy Arthritis Drug, by Type USD Million (2021-2026)
  • Table 214. Italy Arthritis Drug, by Application USD Million (2021-2026)
  • Table 215. Italy Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 216. Italy Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 217. United Kingdom Arthritis Drug, by Type USD Million (2021-2026)
  • Table 218. United Kingdom Arthritis Drug, by Application USD Million (2021-2026)
  • Table 219. United Kingdom Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 220. United Kingdom Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 221. Netherlands Arthritis Drug, by Type USD Million (2021-2026)
  • Table 222. Netherlands Arthritis Drug, by Application USD Million (2021-2026)
  • Table 223. Netherlands Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 224. Netherlands Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 225. Rest of Europe Arthritis Drug, by Type USD Million (2021-2026)
  • Table 226. Rest of Europe Arthritis Drug, by Application USD Million (2021-2026)
  • Table 227. Rest of Europe Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 228. Rest of Europe Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 229. MEA Arthritis Drug, by Country USD Million (2021-2026)
  • Table 230. MEA Arthritis Drug, by Type USD Million (2021-2026)
  • Table 231. MEA Arthritis Drug, by Application USD Million (2021-2026)
  • Table 232. MEA Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 233. MEA Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 234. Middle East Arthritis Drug, by Type USD Million (2021-2026)
  • Table 235. Middle East Arthritis Drug, by Application USD Million (2021-2026)
  • Table 236. Middle East Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 237. Middle East Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 238. Africa Arthritis Drug, by Type USD Million (2021-2026)
  • Table 239. Africa Arthritis Drug, by Application USD Million (2021-2026)
  • Table 240. Africa Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 241. Africa Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 242. North America Arthritis Drug, by Country USD Million (2021-2026)
  • Table 243. North America Arthritis Drug, by Type USD Million (2021-2026)
  • Table 244. North America Arthritis Drug, by Application USD Million (2021-2026)
  • Table 245. North America Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 246. North America Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 247. United States Arthritis Drug, by Type USD Million (2021-2026)
  • Table 248. United States Arthritis Drug, by Application USD Million (2021-2026)
  • Table 249. United States Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 250. United States Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 251. Canada Arthritis Drug, by Type USD Million (2021-2026)
  • Table 252. Canada Arthritis Drug, by Application USD Million (2021-2026)
  • Table 253. Canada Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 254. Canada Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 255. Mexico Arthritis Drug, by Type USD Million (2021-2026)
  • Table 256. Mexico Arthritis Drug, by Application USD Million (2021-2026)
  • Table 257. Mexico Arthritis Drug, by Route of Administration USD Million (2021-2026)
  • Table 258. Mexico Arthritis Drug, by Arthritis USD Million (2021-2026)
  • Table 259. Research Programs/Design for This Report
  • Table 260. Key Data Information from Secondary Sources
  • Table 261. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Arthritis Drug: by Type USD Million (2015-2020)
  • Figure 5. Global Arthritis Drug: by Application USD Million (2015-2020)
  • Figure 6. Global Arthritis Drug: by Route of Administration USD Million (2015-2020)
  • Figure 7. South America Arthritis Drug Share (%), by Country
  • Figure 8. Asia Pacific Arthritis Drug Share (%), by Country
  • Figure 9. Europe Arthritis Drug Share (%), by Country
  • Figure 10. MEA Arthritis Drug Share (%), by Country
  • Figure 11. North America Arthritis Drug Share (%), by Country
  • Figure 12. Global Arthritis Drug share by Players 2020 (%)
  • Figure 13. Global Arthritis Drug share by Players (Top 3) 2020(%)
  • Figure 14. Global Arthritis Drug share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 18. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 19. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 20. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Amgen Inc. (United States) Revenue: by Geography 2020
  • Figure 22. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 24. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 25. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2020
  • Figure 26. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 28. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 29. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 30. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2020
  • Figure 32. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 33. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 34. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 35. Sanofi S.A. (France) Revenue: by Geography 2020
  • Figure 36. Global Arthritis Drug: by Type USD Million (2021-2026)
  • Figure 37. Global Arthritis Drug: by Application USD Million (2021-2026)
  • Figure 38. Global Arthritis Drug: by Route of Administration USD Million (2021-2026)
  • Figure 39. South America Arthritis Drug Share (%), by Country
  • Figure 40. Asia Pacific Arthritis Drug Share (%), by Country
  • Figure 41. Europe Arthritis Drug Share (%), by Country
  • Figure 42. MEA Arthritis Drug Share (%), by Country
  • Figure 43. North America Arthritis Drug Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novartis AG (Switzerland)
  • Eli Lilly and Company (United States)
  • Amgen Inc. (United States)
  • Merck & Co., Inc. (United States)
  • Bristol-Myers Squibb Company (United States)
  • Pfizer Inc. (United States)
  • Johnson & Johnson (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Bayer AG (Germany)
  • Sanofi S.A. (France)
Select User Access Type

Key Highlights of Report


Mar 2021 224 Pages 94 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Arthritis Drug Quantitative research analysis
Global Arthritis Drug Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Arthritis Drug Report?

Have a Query? Click Here

Other Related Reports

Oxytocic Pharmaceuticals Comprehensive Study by Route of Administration (Intramuscular, Intravenous Injection/Infusion), Indication (Abortion Induced Incomplete, Inevitable Abortion, Postpartum Hemor...
$ 3750
Acemetacin Comprehensive Study by Application (Rheumatoid Arthritis, Osteoarthritis, Lower Back Pain, Postoperative Pain Reduction, Inflammation), End User (Hospitals, Pharmacy) Players and Region - ...
$ 3500
Ivosidenib Drugs Comprehensive Study by Type (60 Tablets, 30 Tablets), Application (Hospital, Pharmacy) Players and Region - Global Market Outlook to 2026
$ 3500
Tuberculosis Vaccines Comprehensive Study by Type (Immunotherapeutic Vaccines, Booster Vaccines, Others), Application (Hospitals, Clinics, Others), Testing Type (Tuberculin Skin Test (TST), TB Blood ...
$ 3500
Sulbactam Pivoxil Comprehensive Study by Application (Pharmaceutical, Research, Biosciences, Others), Form (Tablets, Powder, Suspension), Distribution Channel (Hospitals Pharmacies, Medical Stores, O...
$ 3450
Benzocaine Drugs Comprehensive Study by Type (Gel, Aerosol, Paste, Cream), Application (Dental Clinics, Hospital, Pharmacy/Drugstore), Indication (Skin Irritation, Wounds, Ulcers, Hemorrhoids, Others...
$ 3450